Association of deletion polymorphisms GSTT1 and GSTM1 with increased activity of hepatic transaminases in the blood of patients receiving anti-tuberculosis drug therapy
https://doi.org/10.25789/YMJ.2022.79.06
Abstract
Tuberculosis is one of the most common infectious diseases worldwide. According to the approved clinical recommendations, combined anti-tuberculosis therapy with isoniazid, rifampicin, pyrazinamide and ethambutol. Isoniazid is one of the most effective anti-tuberculosis drugs for the treatment of drug–sensitive tuberculosis, however, it has a wide range of undesirable side effects, including drug-induced liver injury. The enzyme glutathione S-transferase is involved in the detoxification of toxic metabolites of isoniazid. There are a number of studies in which the role of deletion genotypes GSTM1 and GSTT1 of the enzyme glutathione S-transferase has been investigated and established, both individually and in combination to increase the frequency of undesirable adverse reactions when using drugs. However, the data obtained are ambiguous and contradictory. In this regard, we have presented an article aimed at studying the effect of polymorphic genes GSTM1 and GSTT1 on the activity of alanine aminotransferase and aspartate aminotransferase in blood serum in patients with newly diagnosed tuberculosis of the respiratory system. Preliminary results of our study showed that carrying a combination of deletion genotypes in the GSTM1 and GSTT1 genes statistically significantly increases the activity of ALT and AST in tuberculosis therapy in patients of Yakut nationality. An increase in ALT and AST levels in the blood indicates the likelihood of hepatocellular liver damage during anti-tuberculosis therapy in carriers of a combination of deletion genotypes (GSTM1(del)/GSTT1(del)) of the enzyme glutathione-S transferase.
About the Authors
V. M. Nikolaev
Yakut Scientific Center for Complex Medical Problems
Russian Federation
Russian Federation
Nikolaev Vyacheslav Mikhailovich – PhD, Senior Researcher, Department of Epidemiology of Chronic Noncommunicable Diseases
N. M. Krasnova
FSAEI HE M.K. Ammosov North-Eastern Federal University
Russian Federation
Russian Federation
Krasnova Natalia Mikhailovna – Candidate of Medical Sciences, Associate Professor, Medical Institute
E. K. Rumyantsev
Yakut Scientific Center for Complex Medical Problems
Russian Federation
Russian Federation
Rumyantsev Egor Konstantinovich – junior researcher of the Arctic Medical Center
E. S. Prokopyev
E.N. Andreev Scientific and Practical Center "Phthisiology"
Russian Federation
Russian Federation
Prokopiev Egor Spiridonovich – Director
A. F. Kravchenko
E.N. Andreev Medical Sciences scientific and practical center "Phthisiology"
Russian Federation
Russian Federation
Kravchenko Alexandr Fedorovich – Doctor
S. I. Sofronova
Yakut Scientific Center for Complex Medical Problems
Russian Federation
Russian Federation
Sofronova Sargylaana Ivanovna – Candidate of Medical Sciences, Head of the Scientific and Organizational and Information and Publishing Department
D. A. Sychev
Russian Academy of Sciences, Russian Medical Academy of Continuous Professional Education of the Ministry of Health of Russia
Russian Federation
Russian Federation
Sychev Dmitry Alekseevich – Doctor of Medical Sciences rector, professor, academician
References
1. Babushkina, A. A. Some parameters of the functional state of the liver in the intensive phase of anti-tuberculosis chemotherapy in patients of the Tyumen OPTD / A.A. Babushkina, I.N. Okhotina, S.P. Cherkasova // Medical Science and Education of the Urals. - 2020. - T. 21, № 1 (101). - Р. 107-110.
2. Vasilyeva I.A. Epidemiological situation in tuberculosis during the years of the COVID-19 pandemic - 2020-2021 / I.A. Vasilyeva, V.V. Testov, S.A. Sterlikov // Tuberculosis and lung diseases. - 2022. - T. 100, No. 3. - P. 6-12. http://doi.org/10.21292/2075-1230-2022-100-3-6-12
3. Influence of the type of acetylation on the frequency of isoniazid hepatotoxicity in patients with newly diagnosed respiratory / Krasnova N.M. Evdokimova N.E. Egorova A.A. [et al.]// Antibiotics and chemotherapy. 2020. V. 65. No. 7-8. - P. 31-36
4. Possibilities of clinical pharmacogenetics in the personalized use of antibacterial drugs / E.I. Kondratyeva, O.G. Novoselova, N.V. Petrova et.al. // Medical genetics. - 2015. - T.14. - No. 12 (162). – P.11-20
5. Ivanova D.A. Undesirable adverse reactions in the treatment of patients with tuberculosis / D.A. Ivanova // Tuberculosis and Lung Diseases 2011. No. 6. – P. 60–9.
6. Clinical guidelines Tuberculosis in adults, 2020.
7. Krasnova N.M. Isoniazid-induced liver injury: pharmacogenetic aspects / N.M. Krasnova, V.M. Nikolaev // Russian Journal of Personalized Medicine. 22022;2(3):38-46. DOI: 10.18705/2782-3806-2022-2-3-38-46
8. Order of the Ministry of Health of the Russian Federation of April 5, 2019 No. 199 “On approval of the departmental target program “Prevention and control of socially significant infectious diseases”
9. Applied pharmacogenetics: monograph / Sh.P. Abdullaev, D.A. Sychev A.S. Ametov [et.al.]; under the editorship of d.m.s., professor, corresponding member. RAS D.A. Sychev. – M.: Triada, 2021. - 496 p.
10. Russian statistical yearbook. 2021: Stat. / Rosstat. - P76 M., 2021 - 692 p. https://rosstat.gov.ru/folder/210/document/12994.
11. Snalina N.E., Sychev D.A. Genetic predictors of isoniazid hepatotoxicity // Molecular Medicine. 2018; (2): -https://doi.org/10.29296/24999490-2018-02-04
12. Stepanova N.A., Galimzyanov Kh.M., Kantemirova B.I. Syndrome of intoxication in patients with pulmonary tuberculosis depending on the polymorphism of the genes of the glutathione transferase system // Journal of Infectology. - 2017. - V.9. - No. 2. - P. 13-16. DOI:10.22625/2072-6732-2017-9-2-13-16
13. Antituberculosis Agents. In: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; September 22, 2017.
14. Chanhom N, Wattanapokayakit S, Satproedprai N, et al. CYP2E1, GSTM1, and GSTT1 genetic polymorphisms and their associations with susceptibility to antituberculosis drug-induced liver injury in Thai tuberculosis patients. Heliyon. 2021;7(4):e06852. Published 2021 Apr 20. doi:10.1016/j.heliyon.2021.e06852
15. Chatterjee S, Lyle N, Mandal A, Kundu S. GSTT1 and GSTM1 gene deletions are not associated with hepatotoxicity caused by antitubercular drugs. J Clin Pharm Ther. 2010;35(4):465- 470. doi:10.1111/j.1365-2710.2009.01101.x
16. Borisov S.E. et al. Effectiveness and safety of the bedaquiline-containing six-month chemotherapy regimens in pulmonary tuberculosis patients. // Tuberculosis and socio-important diseases. – 2015. – № 3. – P. 30-49.
17. Ginsberg G, Smolenski S, Hattis D, Guyton KZ, Johns DO, Sonawane B. Genetic Polymorphism in Glutathione Transferases (GST): Population distribution of GSTM1, T1, and P1 conjugating activity. J Toxicol Environ Health B Crit Rev. 2009;12(5-6):389-439. doi:10.1080/10937400903158375
18. Hassan HM, Guo HL, Yousef BA, Luyong Z, Zhenzhou J. Hepatotoxicity mechanisms of isoniazid: A mini-review. J Appl Toxicol. 2015;35(12):1427-1432. doi:10.1002/jat.3175
19. Hayes JD, McLellan LI. 1999. Glutathione and glutathione-dependent enzymes represent a co-ordinately regulated defence against oxidative stress. Free Radic. Res. 31:273–300
20. Huang YS. Genetic polymorphisms of drug-metabolizing enzymes and the susceptibility to antituberculosis drug-induced liver injury. Expert Opin Drug Metab Toxicol. 2007;3(1):1-8. doi:10.1517/17425255.3.1.1
21. https://www.who.int/ru/news-room/factsheets/detail/tuberculosis
22. Ikeda T. Drug-induced idiosyncratic hepatotoxicity: prevention strategy developed after the troglitazone case. Drug Metab Pharmacokinet. 2011;26(1):60-70. doi:10.2133/dmpk.dmpk-10-rv-090
23. Jokhadze T, Buadze T, Gaiozishvili M, Kiria N, Khujadze I, Lezhava T. Georgian Med News. 2019;(296):111-116.
24. Kim SH, Yoon HJ, et al. GSTT1 and GSTM1 null mutations and adverse reactions induced by antituberculosis drugs in Koreans. Tuberculosis (Edinb). 2010;90(1):39-43. doi:10.1016/j.tube.2009.12.001
25. Leiro V, Fernández-Villar A, Valverde D, et al. Influence of glutathione S-transferase M1 and T1 homozygous null mutations on the risk of antituberculosis drug-induced hepatotoxicity in a Caucasian population. Liver Int. 2008;28(6):835- 839. doi:10.1111/j.1478-3231.2008.01700.x
26. Li C, Long J, Hu X, Zhou Y. GSTM1 and GSTT1 genetic polymorphisms and risk of anti-tuberculosis drug-induced hepatotoxicity: an updated meta-analysis. Eur J Clin Microbiol Infect Dis. 2013;32(7):859-868. doi:10.1007/s10096-013-1831-y
27. Liu F, Jiao AX, Wu XR, et al. Impact of glutathione S-transferase M1 and T1 on anti-tuberculosis drug-induced hepatotoxicity in Chinese pediatric patients. PLoS One. 2014;9(12):e115410. Published 2014 Dec 19. doi:10.1371/journal.pone.0115410
28. Meng X, Maggs JL, Usui T, et al. Auto-oxidation of Isoniazid Leads to Isonicotinic-Lysine Adducts on Human Serum Albumin. Chem Res Toxicol. 2015;28(1):51-58. doi:10.1021/tx500285k
29. Metushi I, Uetrecht J, Phillips E. Mechanism of isoniazid-induced hepatotoxicity: then and now. Br J Clin Pharmacol. 2016;81(6):1030- 1036. DOI: 10.1111/bcp.12885
30. Metushi IG, Cai P, Zhu X, Nakagawa T, Uetrecht JP. A fresh look at the mechanism of isoniazid-induced hepatotoxicity. Clin Pharmacol Ther. 2011;89(6):911-914. doi:10.1038/clpt.2010.355
31. Metushi IG, Hayes MA, Uetrecht J. Treatment of PD-1(-/-) mice with amodiaquine and anti-CTLA4 leads to liver injury similar to idiosyncratic liver injury in patients. Hepatology. 2015;61(4):1332-1342. doi:10.1002/hep.27549
32. Monteiro TP, El-Jaick KB, Jeovanio-Silva AL, et al. The roles of GSTM1 and GSTT1 null genotypes and other predictors in anti-tuberculosis drug-induced liver injury. J Clin Pharm Ther. 2012;37(6):712-718. doi:10.1111/j.1365-2710.2012.01368.x
33. O'Connor C, Brady MF. Isoniazid. In: StatPearls. Treasure Island (FL): StatPearls Publishing; April 8, 2022.
34. Perwitasari DA, Atthobari J, Wilffert B. Pharmacogenetics of isoniazid-induced hepatotoxicity. Drug Metab Rev. 2015;47(2):222- 228. doi:10.3109/03602532.2014.984070
35. Pourkeramati A, Zare Mehrjardi E, Dehghan Tezerjani M, Seifati SM. Association of GSTP1, GSTT1 and GSTM1 Gene Variants with Coronary Artery Disease in Iranian Population: A Case-Control Study. Int J Gen Med. 2020;13:249- 259. Published 2020 May 28. doi:10.2147/IJGM.S252552
Review
For citations:
Nikolaev V.M., Krasnova N.M., Rumyantsev E.K., Prokopyev E.S., Kravchenko A.F., Sofronova S.I., Sychev D.A. Association of deletion polymorphisms GSTT1 and GSTM1 with increased activity of hepatic transaminases in the blood of patients receiving anti-tuberculosis drug therapy. Yakut Medical Journal. 2022;(3):25-30. https://doi.org/10.25789/YMJ.2022.79.06
Views:
18
Email this article 